76088 Federal Register / Vol. 85, No. 229 / Friday, November 27, 2020 / Notices 

• lipid disorder 

• metabolic syndrome 

Development Stage 

• Early stage 

Inventors: Kenneth A. Jacobson 

(NIDDK), Anna Junker, Elisa Uliassi 

(NIDDK), Evgeny Kiselev (NIDDK) 

Publications: Junker A, 

Balasubramanian R, Ciancetta A, et al., 

Structure-based design of 3-(4-aryl-1H– 

1,2,3-triazol-1-yl)-biphenyl derivatives 

as P2Y14 receptor antagonists. J. Med. 

Chem., 2016, 59:6149¥6168. 

Intellectual Property: HHS Reference 

No. E–213–2015–0, U.S. Patent No. 

10,683,277, issued June 16, 2020, EP 

Patent Application 16774825.0, filed 

Sept. 23, 2016, Chinese Patent 

Application 201680064441.5, filed Sept. 

23, 2016. 

Licensing Contact: Betty B. Tong, 

Ph.D.; 301–451–7836; tongb@

mail.nih.gov. This notice is made in 

accordance with 35 U.S.C. 209 and 37 

CFR part 404. 

Dated: November 19, 2020. 

Bei Tong, 

Senior Licensing and Patenting Manager, 

National Institute of Diabetes and Digestive 

and Kidney Diseases, Technology 

Advancement Office. 

[FR Doc. 2020–26169 Filed 11–25–20; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Allergy and 

Infectious Diseases; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Allergy and Infectious Diseases Special 

Emphasis Panel NIAID SBIR Phase II Clinical 

Trial Implementation Cooperative Agreement 

(U44 Clinical Trial Required). 

Date: December 18, 2020. 

Time: 2:30 p.m. to 4:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institute of Allergy and 

Infectious Diseases, National Institutes of 

Health, 5601 Fishers Lane, Room 3G31, 

Rockville, MD 20892, (Virtual Meeting). 

Contact Person: Cynthia L. De La Fuente, 

Ph.D., Scientific Review Officer, Scientific 

Review Program, Division of Extramural 

Activities, National Institute of Allergy and 

Infectious Diseases, National Institutes of 

Health, 5601 Fishers Lane, Room 3G31, 

Rockville, MD 20852, 240–669–2740, 

delafuentecl@niaid.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.855, Allergy, Immunology, 

and Transplantation Research; 93.856, 

Microbiology and Infectious Diseases 

Research, National Institutes of Health, HHS) 

Dated: November 20, 2020. 

Tyeshia M. Roberson, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2020–26152 Filed 11–25–20; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HOUSING AND 

URBAN DEVELOPMENT 

[Docket No. FR–6236–N–01] 

Notice of Certain Operating Cost 

Adjustment Factors for 2021 

AGENCY: Office of the Assistant 

Secretary for Housing—Federal Housing 

Commissioner, HUD. 

ACTION: Notice. 

SUMMARY: This notice establishes 

operating cost adjustment factors 

(OCAFs) for project-based assistance 

contracts issued under Section 8 of the 

United States Housing Act of 1937 and 

renewed under the Multifamily Assisted 

Housing Reform and Affordability Act 

of 1997 (MAHRA) for eligible 

multifamily housing projects having an 

anniversary date on or after February 11, 

2021. OCAFs are annual factors used to 

adjust Section 8 rents renewed under 

section 515 or section 524 of MAHRA. 

DATES: Applicability Date: February 11, 

2021. 

FOR FURTHER INFORMATION CONTACT: 

Carissa Janis, Program Analyst, Office of 

Asset Management and Portfolio 

Oversight, Department of Housing and 

Urban Development, 451 7th Street SW, 

Washington, DC 20410; telephone 

number 202–402–2487 (this is not a tollfree number). Hearing- or speechimpaired individuals may access this 

number through TTY by calling the tollfree Federal Relay Service at 800–877– 

8339. 

SUPPLEMENTARY INFORMATION: 

I. OCAFs 

Section 514(e)(2) and section 524(c)(1) 

of MAHRA (42 U.S.C. 1437f note) 

require HUD to establish guidelines for 

the development of OCAFs for rent 

adjustments. Sections 524(a)(4)(C)(i), 

524(b)(1)(A), and 524(b)(3)(A) of 

MAHRA, all of which prescribe the use 

of the OCAF in the calculation of 

renewal rents, contain similar language. 

HUD has therefore used a single 

methodology for establishing OCAFs, 

which vary among states and territories. 

MAHRA gives HUD broad discretion 

in setting OCAFs, referring, for example, 

in sections 524(a)(4)(C)(i), 524(b)(1)(A), 

524(b)(3)(A), and 524(c)(1), to simply 

‘‘an operating cost adjustment factor 

established by the Secretary.’’ The sole 

limitation to this grant of authority is a 

specific requirement in each of the 

foregoing provisions that application of 

an OCAF ‘‘shall not result in a negative 

adjustment.’’ Contract rents are adjusted 

by applying the OCAF to that portion of 

the rent attributable to operating 

expenses exclusive of debt service. 

The OCAFs provided in this notice 

are applicable to eligible projects having 

a contract anniversary date of February 

11, 2021, or after and were calculated 

using the same method as those 

published in HUD’s 2020 OCAF notice 

published on November 22, 2019 (84 FR 

64553). Specifically, OCAFs are 

calculated as the sum of weighted 

component cost changes for wages, 

employee benefits, property taxes, 

insurance, supplies and equipment, fuel 

oil, electricity, natural gas, and water/ 

sewer/trash, using publicly available 

indices. The weights used in the OCAF 

calculations for each of the nine cost 

component groupings are set using 

current percentages attributable to each 

of the nine expense categories. These 

weights are calculated in the same 

manner as in the November 22, 2019, 

notice. Average expense proportions 

were calculated using three years of 

audited Annual Financial Statements 

from projects covered by OCAFs. The 

expenditure percentages for these nine 

categories have been found to be very 

stable over time but using three years of 

data increases their stability. The nine 

cost component weights were calculated 

at the state level, which is the lowest 

level of geographical aggregation with 

enough projects to permit statistical 

analysis. These data were not available 

for the Western Pacific Islands, so data 

for Hawaii were used as the best 

available indicator of OCAFs for these 

areas. 

The best current price data sources for 

the nine cost categories were used in 

calculating annual change factors. StateVerDate Sep<11>2014 19:29 Nov 25, 2020 Jkt 253001 PO 00000 Frm 00085 Fmt 4703 Sfmt 4703 E:\FR\FM\27NON1.SGM 27NON1

jbell on DSKJLSW7X2PROD with NOTICES